These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 8181002)
1. Preliminary chemical, biochemical, and pharmacological characterization of a low molecular weight dermatan sulphate. Ferrari GP; Marchesini D; Maggi AP Carbohydr Res; 1994 Mar; 255():125-32. PubMed ID: 8181002 [TBL] [Abstract][Full Text] [Related]
2. Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Saivin S; Dol F; Caranobe C; Petitou M; Lormeau JC; Sie P; Houin G; Boneu B Thromb Res; 1992 Jun; 66(5):527-35. PubMed ID: 1523609 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of sulodexide. Ofosu FA Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633 [TBL] [Abstract][Full Text] [Related]
4. The synthesis of dermatan sulphate proteoglycans by fetal and adult human articular cartilage. Melching LI; Roughley PJ Biochem J; 1989 Jul; 261(2):501-8. PubMed ID: 2775229 [TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative. Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481 [TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material. Dawes J Thromb Haemost; 1993 Apr; 69(4):339-43. PubMed ID: 8497846 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers. Miglioli M; Pironi L; Ruggeri E; Serra C; Zamboni V; Barbanti M; Canova N; Calanni F; Milani MR; Palazzini E Int J Clin Lab Res; 1997; 27(3):195-8. PubMed ID: 9352383 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency. Saivin S; Boneu B; Ducret F; Pourrat J; Palazzini E; Zamboni W; Duchêne P; Houin G Arzneimittelforschung; 2000 Sep; 50(9):821-6. PubMed ID: 11050699 [TBL] [Abstract][Full Text] [Related]
10. Physico-chemical properties and the structure of dermatan sulfate fractions purified from plasma after oral administration in healthy human volunteers. Volpi N Thromb Haemost; 1996 Mar; 75(3):491-6. PubMed ID: 8701414 [TBL] [Abstract][Full Text] [Related]
11. Dermatan sulfate from beef mucosa: structure, physicochemical and biological properties of fractions prepared by chemical depolymerization and anion-exchange chromatography. Volpi N Carbohydr Res; 1994 Mar; 255():133-44. PubMed ID: 8181003 [TBL] [Abstract][Full Text] [Related]
13. Patterns of uronosyl epimerization and 4-/6-O-sulphation in chondroitin/dermatan sulphate from decorin and biglycan of various bovine tissues. Cheng F; Heinegård D; Malmström A; Schmidtchen A; Yoshida K; Fransson LA Glycobiology; 1994 Oct; 4(5):685-96. PubMed ID: 7881183 [TBL] [Abstract][Full Text] [Related]
14. The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities. Du HY; Ji SL; Song HF; Ye QN; Cao JC Thromb Res; 2007; 119(3):377-84. PubMed ID: 17097136 [TBL] [Abstract][Full Text] [Related]
15. [Dermatan sulfate and the prevention of experimental venous thrombosis]. Desnoyers P; Bara L; Samama M Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877 [TBL] [Abstract][Full Text] [Related]
16. Dermatan sulphate proteoglycans of human articular cartilage. The properties of dermatan sulphate proteoglycans I and II. Roughley PJ; White RJ Biochem J; 1989 Sep; 262(3):823-7. PubMed ID: 2590169 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880 [TBL] [Abstract][Full Text] [Related]
18. Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits. Saivin S; Caranobe C; Petitou M; Sie P; Lormeau JC; Level M; Crepon B; Houin G; Boneu B Br J Haematol; 1992 Apr; 80(4):509-13. PubMed ID: 1581235 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168 [No Abstract] [Full Text] [Related]
20. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Linhardt RJ; al-Hakim A; Liu JA; Hoppensteadt D; Mascellani G; Bianchini P; Fareed J Biochem Pharmacol; 1991 Sep; 42(8):1609-19. PubMed ID: 1930287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]